Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fibrocell Science Inc (NASDAQ:FCSC)

1.03
Delayed Data
As of Jun 24
 +0.0573 / +5.89%
Today’s Change
0.91
Today|||52-Week Range
7.60
-77.36%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$45.2M

Company Description

Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company has a pipeline of therapeutic and aesthetic product development programs based on the first Food and Drug Administration approved cell-based product, LAVIV™ (azficel-T), in aesthetics, all of which are based on the autologous fibroblast cell. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. Fibrocell Science was founded on September 1, 2009 and is headquartered in Exton, PA.

Contact Information

Fibrocell Science, Inc.
405 Eagleview Boulevard
Exton Pennsylvania 19341
P:(484) 713-6000
Investor Relations:

Employees

Shareholders

Individual stakeholders38.07%
Other institutional21.41%
Mutual fund holders10.34%

Top Executives

David M. PernockChairman & Chief Executive Officer
Keith Alan GoldanCFO, Treasurer & Senior Vice President
John MaslowskiVice President-Scientific Affairs
Michael F. MarinoSecretary, Senior Vice President & General Counsel
Kimberly M. SmithController